Key clinical point: Patients who undergo PCI for stable ischemic heart disease continue to accrue major adverse cardiovascular events up to 5 years after stenting.

Major finding: Recipients of second-generation drug-eluting stents had a MACE rate of 5.3% in the first year after PCI, with an additional 8.5% rate beyond year 1 out through year 5.

Study details: This was a post hoc analysis of individual patient-level pooled data on nearly 11,000 participants in 19 prospective, randomized, head-to-head stent trials in patients with SIHD.

Disclosures: The presenter reported no financial conflicts regarding his study, funded by an institutional research grant from the National Heart, Lung, and Blood Institute.